Company news

Galectin Therapeutics Inc. news in 2019

Galectin Therapeutics Inc.'s news releases, calls and decks from 2019, newest first.

View company

Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

December 8, 2019

Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

December 4, 2019

Galectin Therapeutics Reports Q3 2019 Financial Results

November 11, 2019

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

November 10, 2019

Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy

September 16, 2019

Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement

April 14, 2019

Decks in 2019